NetworkNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Moving to Become Trusted Source of Effective Medication-Based Treatments
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-based treatments for mental health and addiction disorders. These strategic moves include developing drug candidates, partnering to advance research and more. The company has partnered with Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University (“JHU”), to lead its planned placebo-controlled study evaluating the science and efficacy of MYCO-001, its lead psilocybin-based drug candidate, in treating nicotine dependence. Mydecine recently reported a positive Pre-Investigational New Drug (“IND”) meeting with the FDA. As a result of the meeting, the company decided to undertake a Phase 2B study and then a Phase 3 study instead of the initial approach in which it intended to undertake a seamless Phase 2/3 clinical trial. “The company’s new approach of separating the trials enables publication of data after each study rather than waiting until both phases are complete,” reports a recent article. “Last August, Mydecine signed a five-year master collaboration agreement with the JHU School of Medicine… This agreement would allow JHU and Mydecine to further advance research on novel psychedelic-based therapies for mental health conditions and addiction disorders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-based treatments for mental health and addiction disorders. These strategic moves include developing drug candidates, partnering to advance research and more. The company has partnered with Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University (“JHU”), to lead its planned placebo-controlled study evaluating the science and efficacy of MYCO-001, its lead psilocybin-based drug candidate, in treating nicotine dependence. Mydecine recently reported a positive Pre-Investigational New Drug (“IND”) meeting with the FDA. As a result of the meeting, the company decided to undertake a Phase 2B study and then a Phase 3 study instead of the initial approach in which it intended to undertake a seamless Phase 2/3 clinical trial. “The company’s new approach of separating the trials enables publication of data after each study rather than waiting until both phases are complete,” reports a recent article. “Last August, Mydecine signed a five-year master collaboration agreement with the JHU School of Medicine… This agreement would allow JHU and Mydecine to further advance research on novel psychedelic-based therapies for mental health conditions and addiction disorders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
